Biopharmaceutical company focused on developing and commercializing novel vaccines.
| Year | Client | Period | Income | Expenses | Doc |
|---|---|---|---|---|---|
| 2026 | DYNAVAX TECHNOLOGIES CORP. |
2nd Quarter (Apr 1 - June 30) 2nd Quarter - Termination (No Activity) |
— | $120,000 | |
| 2026 | DYNAVAX TECHNOLOGIES CORP. |
1st Quarter (Jan 1 - Mar 31) 1st Quarter - Report (No Activity) |
— | $120,000 | |
| 2025 | DYNAVAX TECHNOLOGIES CORP. |
4th Quarter (Oct 1 - Dec 31) 4th Quarter - Report (No Activity) |
— | $120,000 | |
| 2025 | DYNAVAX TECHNOLOGIES CORP. |
3rd Quarter (July 1 - Sep 30) 3rd Quarter - Report (No Activity) |
— | $140,000 | |
| 2025 | DYNAVAX TECHNOLOGIES CORP. |
2nd Quarter (Apr 1 - June 30) 2nd Quarter - Report (No Activity) |
— | $140,000 | |
| 2025 | DYNAVAX TECHNOLOGIES CORP. |
1st Quarter (Jan 1 - Mar 31) 1st Quarter - Report (No Activity) |
— | $100,000 | |
| 2024 | DYNAVAX TECHNOLOGIES CORP. |
4th Quarter (Oct 1 - Dec 31) 4th Quarter - Report (No Activity) |
— | $120,000 | |
| 2024 | DYNAVAX TECHNOLOGIES CORP. |
3rd Quarter (July 1 - Sep 30) 3rd Quarter - Report (No Activity) |
— | $100,000 | |
| 2024 | DYNAVAX TECHNOLOGIES CORP. |
2nd Quarter (Apr 1 - June 30) 2nd Quarter - Report (No Activity) |
— | $110,000 | |
| 2024 | DYNAVAX TECHNOLOGIES CORP. |
1st Quarter (Jan 1 - Mar 31) 1st Quarter - Report (No Activity) |
— | $190,000 |
| Client | Filings | Total Income |
|---|---|---|
| DYNAVAX TECHNOLOGIES CORP. | 20 | — |
| Name | Disclosed Prior Position |
|---|---|
| KATHY KULKARNI | Health Policy Legislative Assistant - Office of Congressman Frank Pallone Jr. |